Pediatric Cardiology

, Volume 39, Issue 6, pp 1188–1193 | Cite as

Prognostic Value of Serum Apelin Level in Children with Heart Failure Secondary to Congenital Heart Disease

  • Doaa El Amrousy
  • Heba El-Mahdy
Original Article


Apelin is an endogenous inotrope that decreased in heart failure (HF). We aimed to evaluate the prognostic value of its level in children with HF due to congenital heart disease (CHD). Sixty children with HF due to CHD were included as a patient group. Sixty healthy children matched for age, sex, and weight served as a control group. Chest X-ray, electrocardiogram (ECG), echocardiography, and laboratory investigations such as complete blood count, c-reactive protein, and serum apelin levels were performed for all included children at admission. All children were followed up for 3 months. Serum apelin level was significantly decreased in patients with HF at admission than healthy control group and this decrease went with advanced stage of HF. Serum apelin levels were significantly decreased in patients with unfavorable prognosis than those with favorable prognosis. At a cutoff lower than 126 ng/l, the sensitivity of serum apelin to predict unfavorable prognosis in children with HF was 96% with a specificity of 82%. Serum apelin level had a significant positive correlation with left ventricular systolic function (P < 0.05). Moreover, it had a significant negative correlation with heart rate, respiratory rate, Ross classification, c-reactive protein, cardiothoracic ratio, and both left and right ventricular dimensions (P < 0.05). Serum apelin level has a good predictive value for adverse outcome in children with HF due to CHD.


Children Serum apelin Prognosis Heart failure 


Compliance with Ethical Standards

Conflict of interest

All authors have no potential conflict of interest to disclose.

Ethical Approval

The study is in accordance with the ethical standards of institutional research committee and with the 1964 Helsinki declaration and its later amendments.

Informed Consent

Informed consents were obtained from all individual participants included in the study.


  1. 1.
    El Amrousy D, Hodeib H, Suliman G, Hablas N, Ramadan E, Esam A (2017) Diagnostic and prognostic value of plasma levels of cardiac myosin binding protein-C as a novel biomarker in heart failure. Pediatr Cardiol J 38(2):418–424CrossRefGoogle Scholar
  2. 2.
    Sayer G, Bhat G (2014) The renin-angiotensin-aldosterone system and heart failure. Cardiol Clin 32(1):21–32CrossRefPubMedGoogle Scholar
  3. 3.
    Ma Y, Yue Y, Ma Y, Zhang Q, Zhou Q, Song Y, Shen Y, Li X, Ma X, Li C, Hanson MA, Han GW, Sickmier EA, Swaminath G, Zhao S, Stevens RC, Hu LA, Zhong W, Zhang M, Xu F (2017) Structural basis for apelin control of the human apelin receptor. Structure 25(6):858–866CrossRefPubMedGoogle Scholar
  4. 4.
    Goidescu CM, Vida-Simiti LA (2015) The apelin-APJ system in the evolution of heart failure. Clujul Med 88(1):1–8CrossRefGoogle Scholar
  5. 5.
    Folino A, Montarolo PG, Samaja M, Rastaldo R (2015) Effects of apelin on the cardiovascular system. Heart Fail Rev 20(4):505–518CrossRefPubMedGoogle Scholar
  6. 6.
    Chandrasekaran B, Dar O, McDonagh T (2008) The role of apelin in cardiovascular function and heart failure. Eur J Heart Fail 10:725–732CrossRefPubMedGoogle Scholar
  7. 7.
    Dalzell JR, Rocchicciol JP, Weir RAP, Jackson CE, Padmanabhan N, Gardner RS, Petrie MC, Mcmurray JJV (2015) The emerging potential of the apelin-APJ system in heart failure. J Card Fail 21(6):489–498CrossRefPubMedGoogle Scholar
  8. 8.
    Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA (2006) Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail 8:355–360CrossRefPubMedGoogle Scholar
  9. 9.
    Goidescu CM, Anton FP, Leucuța DC, Mircea PA, Vida-Simiti LA (2016) Serum level of apelin-13 negatively correlated with NT-pro BNP in heart failure patients. Rev Rom Med Lab 24(4):399–412Google Scholar
  10. 10.
    van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM (2006) Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 48:1217–1224CrossRefPubMedGoogle Scholar
  11. 11.
    Dalzell JR, Jackson CE, Chong KS, McDonagh TA, Gardner RS (2014) Do plasma concentrations of apelin predict prognosis in patients with advanced heart failure? Biomarkers Med 8(6):807–813CrossRefGoogle Scholar
  12. 12.
    Codognotto M, Piccoli A, Zaninotto M, Mion M, Vertolli U, Tona F, Boffa GM (2007) Evidence for decreased circulating apelin beyond heart involvement in uremic cardio-myopathy. Am J Nephrol 27:1–6CrossRefPubMedGoogle Scholar
  13. 13.
    Chen MM, Ashley EA, Deng DX, Tsalenko A, Deng A, Tabibiazar R, Ben-Dor A, Fenster B, Yang E, King JY, Fowler M, Robbins R, Johnson FL, Bruhn L, McDonagh T, Dargie H, Yakhini Z, Tsao PS, Quertermous T et al (2003) Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 108:1432–1439CrossRefPubMedGoogle Scholar
  14. 14.
    Basile G, Crucitti A, Cucinotta MD, Lacquaniti A, Catalano A, Loddo S, Buemi M, Lasco A (2014) Serum levels of apelin-36 are decreased in older hospitalized patients with heart failure. Eur Geriatr Med 5(4):242–245CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Pediatric DepartmentTanta University HospitalTantaEgypt

Personalised recommendations